PEARL Act
- Bill Number
- H.R. 8366
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Civil Rights and Liberties, Minority Issues
- Status
- Introduced
- Latest Action
- 2026-04-20: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-04-30T19:50:18Z
AI-Generated Summary
Purpose
The Pharmacists Ethical Autonomy and Religious Liberties Act (PEARL Act) aims to protect the religious freedom of pharmacists by allowing them to refuse to dispense or sell specific abortion-inducing drugs—mifepristone and misoprostol—without facing penalties, if doing so conflicts with their sincerely held religious beliefs.
Key Provisions
- Protection from Requirements and Penalties: Pharmacists, including those working for private businesses or government agencies, cannot be forced to dispense or sell mifepristone or misoprostol for abortion services if it violates their religious beliefs. No punishments are allowed, such as license revocation or loss of federal funding.
- Private Right of Action: Affected pharmacists can file a lawsuit in federal district court seeking injunctive relief (a court order to stop the requirement or punishment).
- Definition of Pharmacist: A state-licensed individual authorized to practice pharmacy, including dispensing and selling prescription drugs.
Significant Changes to Existing Law
- Overrides any conflicting federal, state, or local laws that might require pharmacists to dispense these drugs or penalize refusal.
- Introduces a federal safeguard specifically for religious objections to these two drugs, which were not explicitly protected in this way before.
Potential Impacts
- Government Agencies: Federal agencies cannot withhold funding from pharmacies or pharmacists for religious refusals; state licensing boards may face lawsuits if they revoke licenses.
- Citizens:
- Pharmacists gain stronger job protections.
- Patients seeking mifepristone or misoprostol for abortions may face delays or need to find alternative providers.
- No Direct International Relations Impact: Focuses on domestic pharmacy practices.
Main Stakeholders Affected
- Pharmacists: Primary beneficiaries with legal protections for religious refusals.
- Pharmacy Employers (private chains, hospitals, government facilities): Must accommodate refusals without penalties.
- Patients: Those needing abortion drugs may experience access barriers.
- State Licensing Boards and Regulators: Restricted from enforcing mandates or punishments.
- Federal Funding Agencies (e.g., those supporting healthcare programs): Prohibited from using funding as leverage.
Notable Legal, Constitutional, or Political Implications
- Legal: Establishes a federal private right of action, enabling quick court intervention; applies nationwide, potentially preempting state laws.
- Constitutional: Bolsters First Amendment protections for religious exercise (sincerely held religious beliefs), similar to existing frameworks like the Religious Freedom Restoration Act (RFRA), but targeted to pharmacists and specific drugs.
- Political: Could spark debates on balancing religious liberty with healthcare access, especially amid ongoing abortion rights discussions post-Roe v. Wade overturn.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2026-04-20: Referred to the House Committee on Energy and Commerce.
- 2026-04-20: Introduced in House
- 2026-04-20: Introduced in House
Bill Versions
- Pharmacists Ethical Autonomy and Religious Liberties Act — issued 2026-04-20 — PDF (2 pages)